In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in Japan

Documenti analoghi

• Postmarket safety communications on drugs approved in Japan: A 25‐year analysis
  di: Yusuke Tanaka, et al.
  Pubblicazione: (2024)
• Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants
  di: Jack Chang, et al.
  Pubblicazione: (2025)
• Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants
  di: Qianwen Wang, et al.
  Pubblicazione: (2025)
• Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
  di: Sean Regan, et al.
  Pubblicazione: (2025)
• Quantification of SARS‐CoV‐2 viral load in patients using time‐to‐results in antigen lateral flow tests
  di: Elsa W. Braunstein, et al.
  Pubblicazione: (2024)